Jupiter Wealth Management LLC Cuts Stock Position in Pfizer Inc. $PFE

Key Points

• Jupiter Wealth Management LLC has reduced its stake in Pfizer by 54.6%, selling 39,150 shares and now holding 32,600 shares valued at approximately $826,000.
• Several institutional investors have significantly increased their holdings in Pfizer, with Brighton Jones LLC boosting its stake by 1,282.4% during the last quarter.
• Analysts have diverse ratings on Pfizer's stock, with a current consensus rating of "Hold" and a consensus price target of $28.12.

Jupiter Wealth Management LLC trimmed its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 54.6% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 32,600 shares of the biopharmaceutical company's stock after selling 39,150 shares during the quarter. Jupiter Wealth Management LLC's holdings in Pfizer were worth $826,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently made changes to their positions in the company. Gould Capital LLC raised its position in shares of Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 493 shares during the last quarter. GKV Capital Management Co. Inc. bought a new position in shares of Pfizer during the first quarter worth about $27,000. North Capital Inc. bought a new position in shares of Pfizer during the first quarter worth about $28,000. Bayforest Capital Ltd bought a new position in shares of Pfizer during the first quarter worth about $28,000. Finally, Bernard Wealth Management Corp. bought a new position in shares of Pfizer during the fourth quarter worth about $30,000. 68.36% of the stock is currently owned by institutional investors.

Pfizer Stock Up 1.1%

Shares of NYSE:PFE traded up $0.27 during mid-day trading on Thursday, hitting $24.84. 36,770,116 shares of the company traded hands, compared to its average volume of 34,782,688. The stock has a market cap of $141.23 billion, a P/E ratio of 13.21, a P/E/G ratio of 0.87 and a beta of 0.55. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $30.43. The stock has a 50-day moving average price of $24.82 and a two-hundred day moving average price of $24.32.

Pfizer (NYSE:PFE - Get Free Report) last announced its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.20. The company had revenue of $14.65 billion for the quarter, compared to analysts' expectations of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.Pfizer's quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 2nd. Investors of record on Friday, July 25th were given a dividend of $0.43 per share. The ex-dividend date of this dividend was Friday, July 25th. This represents a $1.72 annualized dividend and a dividend yield of 6.9%. Pfizer's payout ratio is presently 91.49%.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. Bank of America lifted their target price on Pfizer from $27.00 to $28.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. HSBC decreased their price objective on Pfizer from $27.00 to $26.00 and set a "buy" rating for the company in a report on Monday, May 19th. Jefferies Financial Group boosted their price objective on Pfizer from $32.00 to $33.00 and gave the company a "buy" rating in a report on Wednesday, May 21st. Berenberg Bank decreased their price objective on Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a report on Thursday, May 29th. Finally, Citigroup boosted their price objective on Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a report on Wednesday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Pfizer presently has an average rating of "Hold" and a consensus target price of $28.12.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.